An open-label, multi-centre, randomized study to investigate patient preference on dosing in the once-monthly ibandronate [ibandronic acid] and the once-weekly risedronate [risedronic acid] in Korean women with postmenopausal osteoporosis. A six-month, two-sequence, and two period crossover study.

Trial Profile

An open-label, multi-centre, randomized study to investigate patient preference on dosing in the once-monthly ibandronate [ibandronic acid] and the once-weekly risedronate [risedronic acid] in Korean women with postmenopausal osteoporosis. A six-month, two-sequence, and two period crossover study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Jan 2012

At a glance

  • Drugs Ibandronic acid; Risedronic acid
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Jan 2012 Company (Roche) added as trial sponsor and affiliate and lead trial centre as reported by ClinicalTrials.gov.
    • 27 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top